Substances · Cathinone derivatives
N-Ethylhexedrone (Hexen)
- Preferred name
- N-Ethylhexedrone (Hexen)
- IUPAC name
- 2-(ethylamino)-1-phenylhexan-1-one
- Parent CAS number (reference)
- 802857-66-5
- Molecular formula
- C14H21NO
- Molecular weight
- 219.32 g/mol
- InChIKey
- CWNKMHIETKEBCA-UHFFFAOYSA-N
- PubChem
- CID 134822125
- Source
- PubChem
- Verified synonyms & catalog abbreviations
-
N-Ethylhexedrone Hexen NEH Ethyl-Hexedrone
Matching Listings in This Store's Catalog
Verified Neurochemical & Toxicological Intelligence
N-Ethylhexedrone (Hexen / NEH)
Receptor Telemetry & Mechanism of Action
Potent, selective norepinephrine-dopamine reuptake inhibitor (NDRI) without monoamine-releasing activity. Extending the alpha-side chain by one carbon over NEP increases dopamine uptake blockade >3.5-fold: in HEK293 assays (Eshleman et al., 2019), hDAT IC50 = 46.7 ± 4.0 nM (Ki = 171 ± 38 nM) and hNET IC50 = 97.8 ± 8.3 nM (Ki = 1,259 ± 43 nM), with ~100-fold weaker serotonin inhibition (hSERT IC50 = 4,880 ± 470 nM, Ki = 11,400 ± 1,800 nM). Also exhibits moderate local anesthetic activity and elevated in vitro cytotoxicity in SH-SY5Y neuronal cells.
Biotransformation & Active Metabolites
WHO 42nd ECDD reports mucosal onset within ~2 minutes (peaking at 20–25 minutes) and oral onset at 20–25 minutes (peaking at 50–60 minutes); formal human elimination half-life is unverified.
Temporal Pharmacokinetics
Sharp, hard-hitting dopaminergic rush with moderate local numbing, rapid thought acceleration, ego inflation, and prominent cardiovascular and vasoconstrictive load.
- Onset 20–25 minutes oral (2–8 minutes mucosal)
- Peak Window 50–60 minutes oral (20–90 minutes mucosal)
- Total Window 3–6 hours oral (2–5 hours mucosal)
- Residual / Half-Life 1–8 hours (longer after repeated exposure) of persistent tachycardia, cold extremities, anxiety, and insomnia; human plasma half-life is unverified.
Steep response curve: above 30–40 mg mucosal or 40–50 mg orally, mood elevation is rapidly overtaken by persistent tachycardia, cold hands/feet, and anxiety. Hexen is notorious for a brief 30–60 minute mood-elevating rush followed by up to 8 hours of lingering peripheral adrenergic stimulation—making repeated exposure binges rapidly toxic and exhausting.
Quantitative Response Spectrum (Published Literature)
Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.
5–15 mg oral (5 mg mucosal)
Crisp mental awakening, subtle focus enhancement, and mild alertness.
Slight heart-rate increase and mild mouth/nasal numbing if mucosal.
15–25 mg oral (PsychonautWiki 5–24 mg / TripSit 15–30 mg mucosal)
Functional concentration, heightened motivation, talkativeness, and clean mood lift.
Noticeable pulse increase, appetite suppression, dry mouth, and light sweating.
25–40 mg oral (24–30 mg PW / 30–40 mg TripSit mucosal)
Strong mood-elevating rush, ego inflation, music immersion, disinhibition, and fierce urge to redose as the rush ebbs.
Pronounced and prolonged tachycardia, elevated blood pressure, cold hands and feet (vasoconstriction), and nasal mucosal irritation.
40–50 mg oral (30–40 mg PW / 40–50 mg TripSit mucosal)
Scattered hyper-stimulation, impaired concentration, jittery restlessness, anxiety, and compulsive repeated exposure.
Heavy palpitations, chest tightness, bruxism, nausea, tremors, and temporary erectile dysfunction.
50+ mg oral (40–50+ mg mucosal)
Acute panic, auditory distortions/hallucinations, paranoia, and binge-induced stimulant psychosis.
Severe hypertension, dangerous arrhythmias, peripheral vasospasm, hyperthermia, and seizures.
Interaction Matrix & Critical Contraindications
Critical Hazard — Never Combine
High-affinity dopamine/norepinephrine reuptake blockade paired with MAO inhibition causes fatal hypertensive crisis and arrhythmias.
Additive NDRI cardiac load and severe vasoconstriction create acute risk of myocardial ischemia, stroke, and seizures.
Markedly lowers seizure threshold alongside intense adrenergic stimulation.
Elevated Hazard — Avoid
Exacerbates Hexen's notoriously prolonged heart-rate elevation, hyperthermia, and neurotoxicity.
Masks depressant intoxication, worsens dehydration and cardiovascular stress, and has been co-detected in severe forensic poisonings.
Caution / Receptor Attenuation
Strongly amplifies resting tachycardia, chest anxiety, and paranoid thought loops during Hexen's long adrenergic tail.
Worsens vasoconstriction (cold extremities) and jittery palpitations.
Structural Isomer & Sibling Comparison
Hexen (NEH) is ~3.5-fold more potent at blocking DAT than NEP (hDAT IC50 46.7 nM vs. 165 nM), delivering a sharper, more rush-driven peak with moderate local numbing, but at the cost of stronger vasoconstriction, more persistent heart-rate elevation, and a rougher comedown than NEP. Compared to alpha-PHP (its pyrrolidino analogue), Hexen requires roughly twice the milligram amount (common 25–40 mg vs. 10–25 mg).
Physicochemical Stability & Storage
Form: Fine white to off-white crystalline powder or needles as the hydrochloride salt, producing moderate topical mouth/nasal numbing and mucosal irritation. · Soluble in water, ethanol, methanol, DMF, and DMSO.
Store sealed, dry, and protected from light and heat.
Cross-Tolerance & Dependence Profile
Rapid acute tolerance to mood elevation within 2–3 doses; full cross-tolerance with NEP, cocaine, pyrovalerones, and amphetamines (3–7 days to halve, 1–2 weeks to baseline). High psychological addiction liability driven by compulsive binge repeated exposure.
Chemical Architecture & Structural Profile
N-Ethylhexedrone (Hexen) (2-(ethylamino)-1-phenylhexan-1-one) is a reference compound belonging to the Cathinone derivatives class, characterized by the molecular formula C14H21NO and a molar mass of 219.32 g/mol. The parent molecule is indexed under CAS registry number 802857-66-5 and in the NCBI PubChem database as CID 134822125 (Standard InChIKey: CWNKMHIETKEBCA-UHFFFAOYSA-N).
Citations
- PubChem — PubChem (2026-11-12)
Reference Toxicology & Safety Profile
In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), N-Ethylhexedrone (Hexen) is indexed within the Cathinone structural group. Toxicological notes (PsychonautWiki): exact toxic threshold is unknown. Dependence liability (PsychonautWiki): moderately addictive with a high potential for abuse. Documented cross-tolerance class: norepinephrine|noradrenergic, dopamine, stimulant. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.
Citations
- PubChem — PubChem (2026-11-12)
Analytical Use & Laboratory Notice
This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.
Citations
- Federal Register of Legislation — Therapeutic Goods (Poisons Standard) — Australian Government (2026-11-12)